Drug Profile
MK 4101
Alternative Names: MK-4101Latest Information Update: 08 Aug 2011
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 08 Aug 2011 No development reported - Phase-I for Cancer in USA (unspecified route)
- 09 Dec 2008 Phase-I clinical trials in Cancer in USA (unspecified route)